Latest Breaking News On - Report shows compound - Page 1 : vimarsana.com

FSD Pharma announces Interim Results from First-in-Human Clinical Trial of Lucid-MS for Multiple Sclerosis. The Report Shows Compound to be Safe and Well Tolerated Toronto,.

United statesZeeshan saeedLakshmip kotraAndrzej chruscinskiScientific affairs at lucid psycheceuticalsBiopharma services incNational multiple sclerosis societyExchange commissionLucid psychss incNeither the canadian securities exchangeCompany annual report on formPharma incInterim resultsFirst in human clinical trialReport shows compoundMultiple sclerosis